{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:20:48Z","timestamp":1784733648396,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Doctoral \u201cDirect Access\u201d Research Program of Chongqing","award":["CSTB2022BSXM-JCX0029"],"award-info":[{"award-number":["CSTB2022BSXM-JCX0029"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073170"],"award-info":[{"award-number":["82073170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04176-8","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:44:36Z","timestamp":1768668276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["APX3330 reverses the immunosuppressive tumor microenvironment during colorectal carcinogenesis"],"prefix":"10.1186","volume":"26","author":[{"given":"Lin\u2019ang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyi","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"4176_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.canlet.2021.09.034","volume":"522","author":"N Li","year":"2021","unstructured":"Li N, Lu B, Luo C, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255\u201368.","journal-title":"Cancer Lett"},{"issue":"1","key":"4176_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41575-023-00841-9","volume":"21","author":"CC Murphy","year":"2024","unstructured":"Murphy CC, Zaki TA. Changing epidemiology of colorectal cancer - birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol. 2024;21(1):25\u201334.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4176_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-017-9726-5","volume":"37","author":"DD Huang","year":"2018","unstructured":"Huang DD, Sun WJ, Zhou YW, et al. Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 2018;37(1):173\u201387.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"4176_CR4","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233\u201354.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4176_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","volume":"162","author":"SC Shah","year":"2022","unstructured":"Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology. 2022;162(3):715\u201330. e3.","journal-title":"Gastroenterology"},{"issue":"14","key":"4176_CR6","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837\u201349.","journal-title":"Int J Biol Sci"},{"key":"4176_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016646","volume":"13","author":"J Shan","year":"2022","unstructured":"Shan J, Han D, Shen C, Lei Q, Zhang Y. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol. 2022;13:1016646.","journal-title":"Front Immunol"},{"issue":"7980","key":"4176_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-023-06511-9","volume":"621","author":"C Wang","year":"2023","unstructured":"Wang C, Zheng X, Zhang J, et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023;621(7980):830\u20139.","journal-title":"Nature"},{"issue":"40","key":"4176_CR9","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1038\/s41388-021-01965-5","volume":"40","author":"L Chen","year":"2021","unstructured":"Chen L, Jin XH, Luo J, et al. ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma. Oncogene. 2021;40(40):5925\u201337.","journal-title":"Oncogene"},{"issue":"22","key":"4176_CR10","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1038\/s41388-022-02324-8","volume":"41","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhang X, Xing Z, et al. OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment. Oncogene. 2022;41(22):3131\u201350.","journal-title":"Oncogene"},{"key":"4176_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01526","volume":"11","author":"I Sieminska","year":"2020","unstructured":"Sieminska I, Baran J. Myeloid-Derived Suppressor Cells in Colorectal Cancer. Front Immunol. 2020;11:1526.","journal-title":"Front Immunol"},{"key":"4176_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.dnarep.2018.08.012","volume":"71","author":"AM Whitaker","year":"2018","unstructured":"Whitaker AM, Freudenthal BD. APE1: a skilled nucleic acid surgeon. DNA Repair (Amst). 2018;71:93\u2013100.","journal-title":"DNA Repair (Amst)"},{"issue":"3","key":"4176_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1089\/ars.2008.2194","volume":"11","author":"G Tell","year":"2009","unstructured":"Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1\/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal. 2009;11(3):601\u201320.","journal-title":"Antioxid Redox Signal"},{"issue":"1\u20132","key":"4176_CR14","first-page":"54","volume":"643","author":"MM Georgiadis","year":"2008","unstructured":"Georgiadis MM, Luo M, Gaur RK, Delaplane S, Li X, Kelley MR. Evolution of the redox function in mammalian apurinic\/apyrimidinic endonuclease. Mutat Res. 2008;643(1\u20132):54\u201363.","journal-title":"Mutat Res"},{"key":"4176_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0023-0","author":"F Shah","year":"2017","unstructured":"Shah F, Logsdon D, Messmann RA, Fehrenbacher JC, Fishel ML, Kelley MR. Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1. https:\/\/doi.org\/10.1038\/s41698-017-0023-0.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"4176_CR16","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s10637-020-00927-0","volume":"38","author":"Y Wang","year":"2020","unstructured":"Wang Y, Li X, Zhang L, et al. A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic\/apyrimidinic endonuclease 1. Invest New Drugs. 2020;38(6):1862\u201371.","journal-title":"Invest New Drugs"},{"issue":"5","key":"4176_CR17","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.21873\/invivo.13304","volume":"37","author":"JY Hong","year":"2023","unstructured":"Hong JY, Oh HH, Park SY, Park YL, Cho SB, Joo YE. Expression of Apurinic\/Apyrimidinic endonuclease 1 in colorectal cancer and its relation to tumor progression and prognosis. Vivo. 2023;37(5):2070\u20137.","journal-title":"Vivo"},{"key":"4176_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom13111569","author":"L Sahakian","year":"2023","unstructured":"Sahakian L, Robinson AM, Sahakian L, Stavely R, Kelley MR, Nurgali K. APE1\/Ref-1 as a therapeutic target for inflammatory bowel disease. Biomolecules. 2023:1569. https:\/\/doi.org\/10.3390\/biom13111569.","journal-title":"Biomolecules"},{"key":"4176_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells12141895","author":"MC Malfatti","year":"2023","unstructured":"Malfatti MC, Bellina A, Antoniali G, Tell G. Revisiting two decades of research focused on targeting APE1 for cancer therapy: the pros and cons. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12141895.","journal-title":"Cells"},{"issue":"1","key":"4176_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.drudis.2020.10.015","volume":"26","author":"RA Caston","year":"2021","unstructured":"Caston RA, Gampala S, Armstrong L, Messmann RA, Fishel ML, Kelley MR. The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease. Drug Discov Today. 2021;26(1):218\u201328.","journal-title":"Drug Discov Today"},{"issue":"4","key":"4176_CR21","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3892\/ol.2014.1864","volume":"7","author":"D Lou","year":"2014","unstructured":"Lou D, Zhu L, Ding H, Dai HY, Zou GM. Aberrant expression of redox protein Ape1 in colon cancer stem cells. Oncol Lett. 2014;7(4):1078\u201382.","journal-title":"Oncol Lett"},{"key":"4176_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2024.10.260","author":"Q Chen","year":"2024","unstructured":"Chen Q, Chen T, Xiao H, et al. APEX1 in intestinal epithelium triggers neutrophil infiltration and intestinal barrier damage in ulcerative colitis. Free Radic Biol Med. 2024;225:359\u2013373. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.10.260.","journal-title":"Free Radic Biol Med"},{"issue":"13","key":"4176_CR23","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1158\/0008-5472.CAN-16-3199","volume":"77","author":"D Wang","year":"2017","unstructured":"Wang D, Sun H, Wei J, Cen B, DuBois RN. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 2017;77(13):3655\u201365.","journal-title":"Cancer Res"},{"issue":"12","key":"4176_CR24","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.7150\/thno.32126","volume":"9","author":"ZY Liu","year":"2019","unstructured":"Liu ZY, Zheng M, Li YM, et al. RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression. Theranostics. 2019;9(12):3659\u201373.","journal-title":"Theranostics"},{"key":"4176_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1050245","volume":"14","author":"S Avlas","year":"2023","unstructured":"Avlas S, Kassis H, Itan M, et al. CD300b regulates intestinal inflammation and promotes repair in colitis. Front Immunol. 2023;14:1050245.","journal-title":"Front Immunol"},{"key":"4176_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun"},{"issue":"16","key":"4176_CR27","first-page":"1825","volume":"46","author":"TianyiLC Chen","year":"2024","unstructured":"Chen Tianyi LC, Bao Lingbo, Chen Qian, Hu Nana, Yang Yuxin, Zhang Lei, et al. APE1 mediates the occurrence and development of colitis-associated colorectal cancer through immunosuppressive tumor microenvironment. J Army Med Univ. 2024;46(16):1825\u201337.","journal-title":"J Army Med Univ"},{"issue":"8","key":"4176_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4176_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.","journal-title":"Signal Transduct Target Ther"},{"key":"4176_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000609","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ding Y, Deng Y, Zheng Y, Wang S. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer. J Immunother Cancer. 2020:e000609. https:\/\/doi.org\/10.1136\/jitc-2020-000609.","journal-title":"J Immunother Cancer"},{"key":"4176_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101891","volume":"42","author":"KB Kennel","year":"2021","unstructured":"Kennel KB, Greten FR. Immune cell - produced ROS and their impact on tumor growth and metastasis. Redox Biol. 2021;42:101891.","journal-title":"Redox Biol"},{"issue":"2","key":"4176_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0394632017711055","volume":"30","author":"N Ma","year":"2017","unstructured":"Ma N, Liu Q, Hou L, Wang Y, Liu Z. MDSCs are involved in the protumorigenic potentials of GM-CSF in colitis-associated cancer. Int J Immunopathol Pharmacol. 2017;30(2):152\u201362.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"18","key":"4176_CR33","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1158\/1078-0432.CCR-13-0278","volume":"19","author":"TW Poh","year":"2013","unstructured":"Poh TW, Madsen CS, Gorman JE, et al. Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells. Clin Cancer Res. 2013;19(18):5039\u201352.","journal-title":"Clin Cancer Res"},{"key":"4176_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0410-7","volume":"13","author":"LY OuYang","year":"2015","unstructured":"OuYang LY, Wu XJ, Ye SB, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med. 2015;13:47.","journal-title":"J Transl Med"},{"key":"4176_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03070","volume":"10","author":"C Siret","year":"2019","unstructured":"Siret C, Collignon A, Silvy F, et al. Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. Front Immunol. 2019;10:3070.","journal-title":"Front Immunol"},{"issue":"2","key":"4176_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1099\/jgv.0.000260","volume":"97","author":"MA O\u2019Connor","year":"2016","unstructured":"O\u2019Connor MA, Vella JL, Green WR. Reciprocal relationship of T regulatory cells and monocytic myeloid-derived suppressor cells in LP-BM5 murine retrovirus-induced immunodeficiency. J Gen Virol. 2016;97(2):509\u201322.","journal-title":"J Gen Virol"},{"key":"4176_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers (Basel). 2021:210. https:\/\/doi.org\/10.3390\/cancers13020210.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4176_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105\u201315.","journal-title":"Immunology"},{"issue":"2","key":"4176_CR39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","volume":"66","author":"B Huang","year":"2006","unstructured":"Huang B, Pan PY, Li Q, et al. Gr-1\u2009+\u2009CD115\u2009+\u2009immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123\u201331.","journal-title":"Cancer Res"},{"key":"4176_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010639","author":"J Duan","year":"2025","unstructured":"Duan J, Chen T, Li Q, et al. Protein arginine methyltransferase 6 enhances immune checkpoint blockade efficacy via the STING pathway in MMR-proficient colorectal cancer. J Immunother Cancer. 2025:e010639. https:\/\/doi.org\/10.1136\/jitc-2024-010639.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4176_CR41","first-page":"41","volume":"7","author":"S Lin","year":"2017","unstructured":"Lin S, Wang J, Wang L, et al. Phosphodiesterase-5 Inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res. 2017;7(1):41\u201352.","journal-title":"Am J Cancer Res"},{"issue":"Pt 2","key":"4176_CR42","doi-asserted-by":"publisher","first-page":"142015","DOI":"10.1016\/j.ijbiomac.2025.142015","volume":"307","author":"G Zong","year":"2025","unstructured":"Zong G, Deng R, Pan Y, et al. Ginseng polysaccharides ameliorate colorectal tumorigenesis through Lachnospiraceae-mediated immune modulation. Int J Biol Macromol. 2025;307(Pt 2):142015.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"4176_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/01635581.2023.2274622","volume":"76","author":"F Shao","year":"2024","unstructured":"Shao F, Pan J, Xie Y, et al. Sulforaphane attenuates AOM\/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation. Nutr Cancer. 2024;76(1):137\u201348.","journal-title":"Nutr Cancer"},{"key":"4176_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118260","volume":"333","author":"ZH Lu","year":"2024","unstructured":"Lu ZH, Ding Y, Wang YJ, et al. Early administration of Wumei Wan inhibit myeloid-derived suppressor cells via PI3K\/Akt pathway and amino acids metabolism to prevent colitis-associated colorectal cancer. J Ethnopharmacol. 2024;333:118260.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"4176_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-023-08946-9","volume":"51","author":"PB Siqueira","year":"2024","unstructured":"Siqueira PB, de Sousa Rodrigues MM, de Amorim ISS, et al. The APE1\/REF-1 and the hallmarks of cancer. Mol Biol Rep. 2024;51(1):47.","journal-title":"Mol Biol Rep"},{"key":"4176_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.702890","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Y, Liu Y, Xu J, Liu Y. Gut-Liver axis: liver sinusoidal endothelial cells function as the hepatic barrier in colitis-induced liver injury. Front Cell Dev Biol. 2021;9:702890.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"4176_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020792","volume":"23","author":"J Korbecki","year":"2022","unstructured":"Korbecki J, Barczak K, Gutowska I, Chlubek D, Baranowska-Bosiacka I. CXCL1: gene, promoter, regulation of expression, mRNA stability, regulation of activity in the intercellular space. Int J Mol Sci. 2022;23(2):25.","journal-title":"Int J Mol Sci"},{"key":"4176_CR48","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180580","author":"C Zhuo","year":"2018","unstructured":"Zhuo C, Wu X, Li J, et al. Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer. Biosci Rep. 2018:BSR20180580. https:\/\/doi.org\/10.1042\/BSR20180580.","journal-title":"Biosci Rep"},{"key":"4176_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4030022","author":"JM David","year":"2016","unstructured":"David JM, Dominguez C, Hamilton DH, Palena C. The IL-8\/IL-8R axis: a double agent in tumor immune resistance. Vaccines. 2016:22. https:\/\/doi.org\/10.3390\/vaccines4030022.","journal-title":"Vaccines"},{"issue":"44","key":"4176_CR50","doi-asserted-by":"publisher","first-page":"76843","DOI":"10.18632\/oncotarget.20164","volume":"8","author":"L Wu","year":"2017","unstructured":"Wu L, Deng Z, Peng Y, et al. Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget. 2017;8(44):76843\u201356.","journal-title":"Oncotarget"},{"issue":"Pt A","key":"4176_CR51","doi-asserted-by":"publisher","first-page":"113089","DOI":"10.1016\/j.intimp.2024.113089","volume":"142","author":"X Wang","year":"2024","unstructured":"Wang X, Wang X, Wang D, et al. Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth. Int Immunopharmacol. 2024;142(Pt A):113089.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4176_CR52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41419-021-03788-4","volume":"12","author":"H Liu","year":"2021","unstructured":"Liu H, Ling CC, Yeung WHO, et al. Monocytic MDSC mobilization promotes tumor recurrence after liver transplantation via CXCL10\/TLR4\/MMP14 signaling. Cell Death Dis. 2021;12(5):489.","journal-title":"Cell Death Dis"},{"key":"4176_CR53","doi-asserted-by":"crossref","unstructured":"Korbecki J, Kojder K, Siminska D et al. CC chemokines in a tumor: A review of Pro-Cancer and Anti-Cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci 2020;21(21):8412.","DOI":"10.3390\/ijms21218412"},{"key":"4176_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169927","author":"E Schwarz","year":"2024","unstructured":"Schwarz E, Benner B, Wesolowski R, et al. Inhibition of Bruton\u2019s tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors. JCI Insight. 2024:e169927. https:\/\/doi.org\/10.1172\/jci.insight.169927.","journal-title":"JCI Insight"},{"key":"4176_CR55","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.2147\/CMAR.S197354","volume":"11","author":"Z Chen","year":"2019","unstructured":"Chen Z, Dai W, Yang L, et al. Elevated expression of CXCL16 correlates with poor prognosis in patients with colorectal cancer. Cancer Manag Res. 2019;11:4691\u20137.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"4176_CR56","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2326-6066.CIR-24-0084","volume":"13","author":"S Dong","year":"2025","unstructured":"Dong S, Ye C, Li B, et al. Targeting of tumoral NAC1 mitigates myeloid-derived suppressor cell-mediated immunosuppression and potentiates anti-PD-1 therapy in ovarian cancer. Cancer Immunol Res. 2025;13(2):286\u2013302.","journal-title":"Cancer Immunol Res"},{"key":"4176_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073490","author":"J Korbecki","year":"2021","unstructured":"Korbecki J, Bajdak-Rusinek K, Kupnicka P, et al. The role of CXCL16 in the pathogenesis of cancer and other diseases. Int J Mol Sci. 2021:3490. https:\/\/doi.org\/10.3390\/ijms22073490.","journal-title":"Int J Mol Sci"},{"key":"4176_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.imlet.2018.07.010","volume":"202","author":"M Bauswein","year":"2018","unstructured":"Bauswein M, Singh A, Ralhan A, et al. Human T cells modulate myeloid-derived suppressor cells through a TNF-alpha-mediated mechanism. Immunol Lett. 2018;202:31\u20137.","journal-title":"Immunol Lett"},{"issue":"4","key":"4176_CR59","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell States in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218\u201332.","journal-title":"Nat Rev Cancer"},{"issue":"7967","key":"4176_CR60","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B, Buzzai AC, Shridhar N, et al. CD4(+) t cell-induced inflammatory cell death controls immune-evasive tumours. Nature. 2023;618(7967):1033\u201340.","journal-title":"Nature"},{"issue":"1","key":"4176_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80382-2","volume":"11","author":"A Lalos","year":"2021","unstructured":"Lalos A, Tulek A, Tosti N, et al. Prognostic significance of CD8\u2009+\u2009T-cells density in stage III colorectal cancer depends on SDF-1 expression. Sci Rep. 2021;11(1):775.","journal-title":"Sci Rep"},{"issue":"4","key":"4176_CR62","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547\u201362.","journal-title":"Cancer Cell"},{"issue":"4","key":"4176_CR63","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41579-023-00973-4","volume":"22","author":"MT White","year":"2024","unstructured":"White MT, Sears CL. The microbial landscape of colorectal cancer. Nat Rev Microbiol. 2024;22(4):240\u201354.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"4176_CR64","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.immuni.2022.03.008","volume":"55","author":"K Peuker","year":"2022","unstructured":"Peuker K, Strigli A, Tauriello DVF, et al., et al. Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity. 2022;55(4):701\u201317. e7.","journal-title":"Immunity"},{"issue":"1\u20132","key":"4176_CR65","first-page":"82","volume":"736","author":"B Tudek","year":"2012","unstructured":"Tudek B, Speina E. Oxidatively damaged DNA and its repair in colon carcinogenesis. Mutat Res. 2012;736(1\u20132):82\u201392.","journal-title":"Mutat Res"},{"key":"4176_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2019.102675","volume":"82","author":"M Codrich","year":"2019","unstructured":"Codrich M, Comelli M, Malfatti MC, et al. Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway. DNA Repair. 2019;82:102675.","journal-title":"DNA Repair"},{"key":"4176_CR67","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.ircmb.2021.05.002","volume":"364","author":"S Zhao","year":"2021","unstructured":"Zhao S, Tadesse S, Kidane D. Significance of base excision repair to human health. Int Rev Cell Mol Biol. 2021;364:163\u201393.","journal-title":"Int Rev Cell Mol Biol"},{"key":"4176_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107092","volume":"201","author":"S Gampala","year":"2024","unstructured":"Gampala S, Moon HR, Wireman R, et al. New Ref-1\/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types. Pharmacol Res. 2024;201:107092.","journal-title":"Pharmacol Res"},{"issue":"1","key":"4176_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10151-019-1926-2","volume":"23","author":"DS Keller","year":"2019","unstructured":"Keller DS, Windsor A, Cohen R, Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3\u201313.","journal-title":"Tech Coloproctol"},{"issue":"11","key":"4176_CR70","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439\u201353.","journal-title":"J Exp Med"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04176-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:02:10Z","timestamp":1770840130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04176-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4176"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04176-8","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of human tissue samples for this study was approved by the Ethics Committee of the Army Medical Center of PLA. [Approval NO: 2024 (127)].\u00a0The animal experiments conducted in this study received approval from the Laboratory Animal Welfare and Ethics Committee of the Army Medical University (Third Military Medical University) (Ratification: AMUWEC20247025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The publication has been approved by all co-authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}